Hikma Pharmaceuticals PLC (OTCMKTS:HKMPF – Get Free Report) shares reached a new 52-week high on Thursday . The stock traded as high as $26.50 and last traded at $26.50, with a volume of 881 shares. The stock had previously closed at $24.59.
Analyst Upgrades and Downgrades
Separately, Royal Bank of Canada raised Hikma Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a report on Tuesday, December 10th.
Get Our Latest Analysis on Hikma Pharmaceuticals
Hikma Pharmaceuticals Price Performance
About Hikma Pharmaceuticals
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals.
Featured Articles
- Five stocks we like better than Hikma Pharmaceuticals
- Investing In Automotive Stocks
- Bloom Energy: Powering the Future With Decentralized Energy
- What Are Some of the Best Large-Cap Stocks to Buy?
- Dividend Powerhouses: Blue-Chip Stocks Built for the Long Haul
- What is the S&P 500 and How It is Distinct from Other Indexes
- Why Traders Are Buying the Dip on Johnson & Johnson Stock
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
